What is the recommended starting dose, titration schedule, contraindications, and monitoring for candesartan in an adult with hypertension?

Candesartan for Hypertension

For adults with hypertension, start candesartan at 16 mg once daily and titrate to a target dose of 32 mg once daily for optimal blood pressure control and cardiovascular risk reduction. 1, 2

Starting Dose

• Standard starting dose: 16 mg once daily 1, 2
• Lower starting dose (4-8 mg once daily): Use in patients with:
  • Volume depletion 2
  • Moderate hepatic impairment (Child-Pugh B) 2
  • Elderly patients (≥75 years) where cautious initiation may be warranted
  • Mild-to-moderate renal impairment (no dose adjustment required, but start conservatively) 2

The FDA label explicitly states 16 mg as the usual recommended starting dose for monotherapy in non-volume-depleted patients 2. However, do not initiate candesartan in patients with severe hepatic impairment because the appropriate 8 mg starting dose cannot be given with standard formulations 2.

Titration Schedule

Titrate to 32 mg once daily within 2-4 weeks if blood pressure remains uncontrolled 1, 2. The maximal antihypertensive effect occurs within 4 weeks of any dose adjustment 2.

• Target dose: 32 mg once daily 1, 3, 4, 1
• Doses above 32 mg provide no additional blood pressure reduction 2
• Once-daily dosing is as effective as twice-daily dosing at the same total daily dose 5

Critical point: For heart failure with reduced ejection fraction, the target dose is also 32 mg once daily 3, 4, 6, which is substantially higher than doses commonly used for hypertension alone (4-8 mg daily). Many physicians underdose candesartan—the usual hypertension doses of 4-8 mg are far below the evidence-based target of 32 mg that reduces mortality and morbidity 7.

Blood Pressure Targets

• Stage 1 hypertension (130-139/80-89 mmHg) with ≥10% 10-year ASCVD risk: Initiate pharmacotherapy, target <130/80 mmHg 1
• Stage 2 hypertension (≥140/90 mmHg): Initiate combination therapy with 2 agents from different classes, target <130/80 mmHg 1
• Hypertension with diabetes or CKD: Target <130/80 mmHg 8, 9, 10
• Optimal target per 2024 ESC guidelines: 120-129 mmHg systolic if well tolerated 11

Combination Therapy

For stage 2 hypertension or uncontrolled blood pressure on monotherapy, combine candesartan with:

1. Thiazide/thiazide-like diuretic (preferred combination) 1, 11

   • Hydrochlorothiazide 12.5-25 mg once daily 1, 2
   • Chlorthalidone 12.5-25 mg once daily (preferred over HCTZ due to longer half-life and proven CVD reduction) 1

2. Dihydropyridine calcium channel blocker (alternative combination) 1, 11

   • Amlodipine 5-10 mg once daily

Single-pill combinations are strongly recommended to improve adherence 11. Fixed-dose candesartan/hydrochlorothiazide combinations (16/12.5 mg or 32/12.5 mg or 32/25 mg) are highly effective 2, 12, 13.

Do NOT combine candesartan with ACE inhibitors—this increases risk of hyperkalemia, hypotension, and renal dysfunction without additional benefit 1, 4, 1, 11.

Contraindications

Absolute contraindications:

• Pregnancy (all trimesters) 1
• History of angioedema with any ARB 4, 6
• Bilateral renal artery stenosis 1
• Severe hepatic impairment 2
• Concomitant use with ACE inhibitors or direct renin inhibitors 1, 11

Relative contraindications/cautions:

• Severe renal impairment (CrCl <30 mL/min)—safety not established 2
• Volume depletion—correct before initiating or use lower starting dose 2
• Hyperkalemia (K+ >5.0-5.5 mEq/L) 1

Monitoring

Initial monitoring (2-4 weeks after starting or dose increase): 1

• Serum creatinine and eGFR
• Serum potassium
• Blood pressure (office and/or home measurements)

Ongoing monitoring:

• Recheck electrolytes and renal function at 1,3, and 6 months, then every 6 months 6
• Blood pressure reassessment monthly until controlled, then every 3-6 months 1

Acceptable changes after initiation:

• eGFR decline up to 30% is expected and reflects beneficial intrarenal hemodynamic changes—do NOT discontinue unless decline is >30% or other causes of AKI are present 10
• Serum creatinine increase up to 30% from baseline is acceptable 6
• Potassium elevation to 5.0-5.5 mEq/L can be managed with dietary modification or low-dose diuretics; discontinue if K+ >5.5 mEq/L 6

Common Pitfalls

1. Underdosing: The most common error is stopping at 8-16 mg instead of titrating to the target 32 mg dose. Evidence shows higher doses provide greater cardiovascular benefit, particularly in heart failure 7, 3.

2. Premature discontinuation for asymptomatic hypotension: If blood pressure drops but patient is asymptomatic, continue therapy. Reduce doses of other less-proven antihypertensives (e.g., alpha-blockers) rather than stopping candesartan 3.

3. Overreacting to mild creatinine elevation: A 20-30% increase in creatinine or decline in eGFR is expected and beneficial long-term. Only discontinue if increase is >30% or if AKI from other causes is suspected 10.

4. Combining with ACE inhibitors: This "dual RAAS blockade" increases adverse events (hyperkalemia, hypotension, renal dysfunction) without mortality benefit 4, 11.

5. Inadequate monitoring: Failing to check electrolytes and renal function 2-4 weeks after initiation or dose changes can miss dangerous hyperkalemia or acute kidney injury 1.

Special Populations

Diabetes with hypertension:

• Candesartan is first-line, especially with albuminuria ≥30 mg/g or CKD 8, 9, 10
• Target BP <130/80 mmHg 10

Heart failure with preserved ejection fraction (HFpEF):

• Candesartan reduced HF hospitalizations by 11% in CHARM-Preserved 8, 9
• Target dose: 32 mg once daily 3, 6

Chronic kidney disease:

• Preferred agent for CKD stage 3 or higher, or albuminuria ≥300 mg/g 8, 9
• No dose adjustment needed for mild-moderate renal impairment 2
• Avoid in severe renal impairment (CrCl <30 mL/min) unless under specialist guidance 2

Elderly (≥65 years):

• Same efficacy and tolerability as younger patients 14, 15
• Consider starting at lower dose (8 mg) if frail or multiple comorbidities
• Continue lifelong even beyond age 85 if well tolerated 11